Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease
NCT01666327
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Inflammatory Bowel Disease
Interventions
DRUG:
MT-1303
Sponsor
Tanabe Pharma Corporation